Brittany N. Allen

Array ( [id] => 16728130 [patent_doc_number] => 20210095277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => ANTISENSE OLIGONUCLEOTIDES TARGETING SREBP1 [patent_app_type] => utility [patent_app_number] => 15/733392 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15690 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15294121 [patent_doc_number] => 20190390196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE [patent_app_type] => utility [patent_app_number] => 16/249128 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16249128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16277063 [patent_doc_number] => 10760080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => Anti-TNF compounds [patent_app_type] => utility [patent_app_number] => 16/248912 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 21 [patent_no_of_words] => 18381 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16248912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16728129 [patent_doc_number] => 20210095276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => OLIGONUCLEOTIDES FOR MODULATING ERC1 EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/733391 [patent_app_country] => US [patent_app_date] => 2019-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22459 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16168219 [patent_doc_number] => 10709759 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-07-14 [patent_title] => Self-replicating cell selective gene delivery compositions, methods, and uses thereof [patent_app_type] => utility [patent_app_number] => 16/247022 [patent_app_country] => US [patent_app_date] => 2019-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 53 [patent_no_of_words] => 18655 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16247022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548470 [patent_doc_number] => 20220119811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/733369 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48640 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17875772 [patent_doc_number] => 11447775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => Antisense oligonucleotides targeting alpha-synuclein and uses thereof [patent_app_type] => utility [patent_app_number] => 16/961624 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 28 [patent_no_of_words] => 18633 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16728128 [patent_doc_number] => 20210095275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/733368 [patent_app_country] => US [patent_app_date] => 2019-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19666135 [patent_doc_number] => 12178855 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Compositions and methods for facilitating delivery of synthetic nucleic acids to cells [patent_app_type] => utility [patent_app_number] => 16/961187 [patent_app_country] => US [patent_app_date] => 2019-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 21 [patent_no_of_words] => 26064 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16728127 [patent_doc_number] => 20210095274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => OLIGONUCLEOTIDES FOR MODULATING PIAS4 EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/733367 [patent_app_country] => US [patent_app_date] => 2019-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18762901 [patent_doc_number] => 11813280 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Reducing beta-catenin and IDO expression to potentiate immunotherapy [patent_app_type] => utility [patent_app_number] => 16/958969 [patent_app_country] => US [patent_app_date] => 2019-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 32 [patent_no_of_words] => 24568 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581895 [patent_doc_number] => 20190218556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => COMPOSITIONS AND METHODS OF INHIBITING GENE EXPRESSION IN A LUNG [patent_app_type] => utility [patent_app_number] => 16/233346 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16233346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20316738 [patent_doc_number] => 12455284 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Double-stranded DNA molecule for the detecting and characterizing molecular interactions [patent_app_type] => utility [patent_app_number] => 16/955596 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 18 [patent_no_of_words] => 30790 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14625193 [patent_doc_number] => 20190225964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE [patent_app_type] => utility [patent_app_number] => 16/230927 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20106955 [patent_doc_number] => 12357653 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Compositions comprising circular polyribonucleotides and uses thereof [patent_app_type] => utility [patent_app_number] => 16/772678 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 63 [patent_no_of_words] => 48663 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18467092 [patent_doc_number] => 20230201373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => CRISPR-MEDIATED GENOME EDITING WITH VECTORS [patent_app_type] => utility [patent_app_number] => 16/954171 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16930938 [patent_doc_number] => 20210196827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => FUNCTIONAL NUCLEIC ACID HAVING NUCLEOSIDE ANALOG DRUG INTEGRATED INTO SKELETON, DERIVATIVE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/057525 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14130229 [patent_doc_number] => 20190099504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => METHOD FOR DELIVERY OF BIOLOGICAL MOLECULE TO NERVOUS TISSUE [patent_app_type] => utility [patent_app_number] => 16/217962 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16217962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19258209 [patent_doc_number] => 12018255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Compositions and methods for treating disorders of genomic imprinting [patent_app_type] => utility [patent_app_number] => 16/770877 [patent_app_country] => US [patent_app_date] => 2018-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 29 [patent_no_of_words] => 24874 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16770877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16105717 [patent_doc_number] => 10695443 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => Exosome transfer of nucleic acids to cells [patent_app_type] => utility [patent_app_number] => 16/201937 [patent_app_country] => US [patent_app_date] => 2018-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4875 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16201937 [rel_patent_id] =>[rel_patent_doc_number] =>)